13F reference period
n/a
Security Snapshot
Senti Biosciences, Inc. - Common Stock, $0.0001 par value (SNTI) Institutional Ownership
CUSIP: 81726A100
13F Institutional Holders and Ownership History from Q2 2022 to Q4 2025
Institutions Reporting
Shares (Excl. Options)
n/a
Price
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value
- Symbol
- SNTI on Nasdaq
- Shares outstanding
- 31,203,430
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- SNTI - Senti Biosciences, Inc. - Common Stock, $0.0001 par value is tracked under CUSIP 81726A100.
- 13F reference-period holder data is not available.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder data for the Q2 2026 reference period is not available.
- Available periods remain in the history table; they do not substitute for the headline period.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Schedule 13D/G
Open SEC evidence
Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.
Security key
81726A100
13F reference period
n/a
13F holders
13D/G owners
3
CIK / CUSIP context first
SNTI full holder history
Senti Biosciences Holdings, Inc. SEC filings
Senti Biosciences Holdings, Inc. company facts
Senti Biosciences Holdings, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 81726A100:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
SNTI
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BAYER HEALTHCARE LLC | 20% | $21,561,396 | 6,142,848 | Bayer HealthCare LLC | 10 Mar 2025 | |||
| New Enterprise Associates 15, L.P. | 12% | 3,775,615 | New Enterprise Associates 15, L.P. | 27 Mar 2026 | ||||
| Lonsdale Joe | 1% | 253,755 | 8VC GP I, LLC | 31 Mar 2025 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
15
Headline period
n/a
Rows shown
1-15 of 15
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 0 | $0 | -$357,795 | 0 | |
| 2025 Q3 | 253,755 | $357,795 | $1.41 | 1 | |
| 2025 Q2 | 253,755 | $535,423 | $2.11 | 1 | |
| 2025 Q1 | 253,755 | $852,617 | $3.36 | 1 | |
| 2024 Q4 | 253,755 | $890,680 | -$108,588 | $3.51 | 1 |
| 2024 Q3 | 301,803 | $682,074 | -$3,229,173 | $2.26 | 2 |
| 2024 Q2 | 7,852,373 | $2,167,022 | -$200,934 | $0.28 | 18 |
| 2024 Q1 | 10,994,171 | $4,145,409 | -$257,675 | $0.38 | 27 |
| 2023 Q4 | 11,461,121 | $7,564,707 | -$1,232,771 | $0.66 | 25 |
| 2023 Q3 | 12,038,399 | $5,018,240 | -$89,453 | $0.41 | 24 |
| 2023 Q2 | 12,200,284 | $7,637,336 | -$267,542 | $0.63 | 27 |
| 2023 Q1 | 12,610,070 | $14,256,476 | +$192,588 | $1.18 | 24 |
| 2022 Q4 | 12,403,151 | $16,580,774 | -$1,583,124 | $1.41 | 26 |
| 2022 Q3 | 13,467,057 | $27,830,384 | +$3,545,876 | $2.17 | 22 |
| 2022 Q2 | 11,903,638 | $22,079,000 | +$22,079,000 | $1.96 | 18 |